We also demonstrate that CTLA4-FasL confers a specific and highly effective killing of tumor cells of the B cell lineage, both in-vitro and in-vivo, indicating that CTLA4-FasL might have a possible role as a new anti-cancer agent. The gene discussed is FASLG; the disease is neoplasm.